[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pathology\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pathology":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,42,67,93,118,141,173,203,225,255,282,316,337],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100456045","evaluation-of-methodological-and-technical-developments-to-improve-the-quality-and-comfort-of-magnetic-resonance-imaging-exam-on-voluntary-subjects-100456045",false,"NCT05218460","Evaluation of Methodological and Technical DEvelopmeNts to Improve the Quality and Comfort of Magnetic Resonance Imaging Exam on Voluntary Subjects","EDEN","Inclusion Criteria for all subjects :\n\n* to be over 18 year-old,\n* to be enrolled in a social security plan,\n* to have underwent a pre-inclusion medical examination,\n* to give a written consent.\n\nInclusion Criteria for volunteers with pathology :\n\n\\- person with a pathology characterized by a functional and \u002F or morphological alteration that may have an impact on the data collected (images, physiological signals, ...).\n\nExclusion Criteria for all subjects :\n\n* any contraindication to MR examination (active medical device, ferromagnetic foreign body, pregnancy, morbid obesity, claustrophobia, … ),\n* subject under a measure of legal protection,\n* Person who refuses to be informed by a doctor in th event of a fortuitus discovery of an abnormality on the MRI examination requiring additionnal examinations or specific treatment.",true,"ALL","18 Years",{"count":20,"type":21},720,"ESTIMATED","INTERVENTIONAL",[24],"NA","The EDEN study will make it possible to evaluate one or more development phases (from design to validation through optimization) of a method or a technique on voluntary subjects, in normal or pathological condition.",[27,28],"Healthy","Pathology","RECRUITING","2026-06-16",{"date":32,"type":33},"2026-06-17","ACTUAL",{"date":35,"type":33},"2022-05-23",{"date":37,"type":21},"2027-05-23",{"name":39,"class":40},"Central Hospital, Nancy, France","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":50,"minAge":4,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100612392","clinical-translation-research-on-a-multi-omics-breast-cancer-distant-metastasis-prediction-model-empowered-by-artificial-intelligence-100612392","NCT07252986","Clinical Translation Research on a Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence","A Multi-omics Breast Cancer Distant Metastasis Prediction Model Empowered by Artificial Intelligence and Its Clinical Translation Research","COMPASS-BC","Inclusion Criteria:\n\n1. Female patients pathologically diagnosed with breast cancer at our hospital or participating centers between January 1, 2000, and December 30, 2028.\n2. Must meet one of the following: 1) Initially diagnosed with breast cancer at our hospital, has developed distant metastasis (liver, bone, lung, or brain), and has a biopsy or surgical specimen from the metastatic site stored at our hospital, with complete clinical information available. 2) Primary tumor specimen is not at our hospital, but a biopsy or surgical specimen from a distant metastatic site (liver, bone, lung, brain) is stored at our hospital.\n\nExclusion Criteria:\n\n1. Concomitant metastatic malignancy from another primary cancer.\n2. Incomplete clinical information.","FEMALE",{"count":52,"type":21},2000,"OBSERVATIONAL","Breast cancer is one of the most common malignancies in women worldwide, and distant metastasis is the main cause of poor prognosis and death. This project aims to construct a precision prediction system based on multi-omics (digital pathology, immunohistochemistry, proteomics, gene sequencing) and artificial intelligence to predict distant and organ-specific metastasis (bone, lung, liver, brain) in breast cancer, analyze its mechanisms, and provide new solutions for precision medicine.",[56,57,28],"Breast","Breast Cancer","2026-02-27",{"date":60,"type":33},"2026-03-03",{"date":62,"type":33},"2025-12-01",{"date":64,"type":21},"2028-12-30",{"name":66,"class":40},"Second Affiliated Hospital, School of Medicine, Zhejiang University",{"id":68,"slug":69,"hasResults":11,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":4,"eligibilityCriteria":73,"healthyVolunteers":11,"sex":17,"minAge":74,"maxAge":75,"enrollmentInfo":76,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":78,"conditions":79,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":41},"100606606","prospective-cohort-study-on-the-relationship-between-exosomal-peroxiredoxin-1-prdx1-and-postoperative-liver-metastasis-100606606","NCT07177742","Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis","Prospective Cohort Study on the Relationship Between Peroxiredoxin 1 (PRDX1) in Blood Exosomes From Colorectal Cancer Radical Resection Specimens and Postoperative Liver Metastasis","Inclusion Criteria:\n\n* Age between 19-80 years old, gender not limited;\n\n  * Can comply with the requirements of the research visit plan and other protocols;\n\n    * Voluntarily participate and sign an informed consent form; ④ Diagnosed with colon adenocarcinoma through pathological examination; ⑤ Patients who have completed colorectal radical surgery.\n\nExclusion Criteria:\n\n* Patients who cannot complete radical surgery for colorectal cancer;\n\n  * Patients with liver diseases (chronic hepatitis B, hepatitis C, severe fatty liver, cirrhosis);\n\n    * Patients who require combined organ resection;\n\n      * Combine patients with other malignant tumors or blood or immune system diseases; ⑤ Prior to tumor resection, any anti-tumor treatment, including radiotherapy, chemotherapy, and molecular targeted therapy, has been performed; ⑥ After surgery, it was found that the mesenteric vein branch of the specimen could not obtain blood due to severe infiltration or other reasons.\n\n        * Patients with severe postoperative complications leading to delayed treatment (Clavien-Dindo grade III or above).","19 Months","80 Months",{"count":77,"type":21},260,"The occurrence of liver metastasis after curative surgery for resectable colorectal cancer is an important cause of death for patients. Accurately identifying high-risk patients for metastasis and intervening in them has important clinical significance. The pathological examination of surgical specimens failed to fully utilize valuable specimen information and accurately predict liver metastasis; The biomarkers secreted by tumors are metabolized in the liver through the portal vein, especially the particles such as extracellular vesicles secreted by tumors, which are ultimately diluted in peripheral blood and cannot be effectively detected. Our research group extracted an average of 11.25ml of blood (named blood derived from portal vein branch specimens, sdBlood for short) from 8 colorectal cancer radical surgery specimens. Compared with peripheral blood, protein mass spectrometry analysis revealed a significant increase in exosome proteins such as peroxidized redox protein 1 (PRDX1), which are highly correlated with metastasis. This project innovatively uses sdBlood, which has been overlooked by routine pathological examination, to detect the exosomal protein PRDX1 in sdBlood, which is significantly higher than the peripheral blood concentration. A prospective cohort study was established, including 252 patients with pathologically confirmed colorectal cancer after radical surgery. The incidence and time of liver metastasis were followed up and observed. Cox regression statistical analysis was used to determine the correlation between this marker and metastasis and determine its critical value, providing a basis for clinical diagnosis and treatment.",[80,81,28,82,83],"Colorectal Cancer","Liver Metastases From Colorectal Cancer","Exosome","Peroxidized Redox Protein 1","2026-02-03",{"date":86,"type":33},"2026-02-06",{"date":88,"type":33},"2021-02-15",{"date":90,"type":21},"2026-11-30",{"name":92,"class":40},"Mu-qing Yang",{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":100,"enrollmentInfo":101,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":103,"conditions":104,"keywords":108,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":41},"100424601","comparation-of-endoscopic-biopsy-and-postoperative-specimen-for-the-molecular-diagnosis-of-gastric-cancer-100424601","NCT04809025","Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer","EBPS","Inclusion Criteria:\n\n1. Lower age limit of research subjects 18 years old and upper age limit of 75 years old.\n2. Histologically proven primary gastric adenocarcinoma (Diagnostic biopsies must be collected within 12 months prior to enrollment).\n3. Written informed consent from the patient.\n4. Patients planned for radical R0 gastrectomy.\n\nExclusion Criteria:\n\n1. Female in pregnancy or lactation.\n2. Patients with gastric cancer who can not undergo tumor resection\n3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases.\n4. Patients with poor compliance or considered to be poor compliance.\n5. Patients received any anticancer drugs, biotherapy, radiotherapy or immunotherapy within 4 weeks before or after enrollment.\n6. Patients after organ transplantation, long-term need to take immunosuppressants, autoimmune diseases.","75 Years",{"count":102,"type":21},510,"This study aims to test the hypothesis that the diagnosis for histological type, histological grade, LAUREN type, HER-2 expression, MSI\u002FdMMR status, and EBV status in gastric cancer is at least as reliable when performed on endoscopic biopsy specimens as on surgical resection specimens.",[105,106,107,28],"Stomach Neoplasms","Endoscopy","Biopsy",[105,106,107,28],"2025-09-24",{"date":111,"type":33},"2025-09-29",{"date":113,"type":33},"2021-05-24",{"date":115,"type":21},"2026-09-01",{"name":117,"class":40},"Fudan University",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":124,"enrollmentInfo":125,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":127,"conditions":128,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":41},"100605740","deep-learning-for-automated-discrimination-between-stage-t1-t2-and-t3-renal-cell-carcinoma-on-contrast-enhanced-ct-100605740","NCT07166445","Deep Learning for Automated Discrimination Between Stage T1-T2 and T3 Renal Cell Carcinoma on Contrast-Enhanced CT","Inclusion Criteria:\n\n1. Histopathologically confirmed renal cell carcinoma on postoperative specimen.\n2. Preoperative contrast-enhanced CT performed at our institution with slice thickness ≤ 1 mm and complete DICOM datasets.\n3. Postoperative pathologic staging clearly defined as pT1a-T2b or pT3a.\n4. CT image quality deemed adequate for analysis.\n\nExclusion Criteria:\n\n* 1\\. Pathologic subtype other than RCC. 2. Images with severe artifacts.","85 Years",{"count":126,"type":21},1000,"This study aims to develop and validate a contrast-enhanced CT-based deep-learning model for automatic and accurate preoperative discrimination between T1-T2 and T3 renal cell carcinoma. By quantifying the model's diagnostic performance on an independent test set-using AUC, sensitivity, specificity, positive\u002Fnegative predictive values, and decision-curve analysis-we will establish a decision-support tool that can be seamlessly integrated into clinical PACS, thereby reducing staging errors, refining surgical planning, and improving patient outcomes.",[129,130,28,131],"Carcinoma, Renal Cell","Diagnostic Imaging","Deep Learning","2025-09-03",{"date":134,"type":33},"2025-09-10",{"date":136,"type":33},"2024-09-01",{"date":138,"type":21},"2027-12-01",{"name":140,"class":40},"Peking University First Hospital",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":50,"minAge":18,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":22,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":41},"100497748","assessment-of-womens-sexual-quality-of-life-after-benign-adnexal-surgery-using-vnotes-approach-100497748","NCT05761275","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach","Assessment of Women's Sexual Quality of Life After Benign Adnexal Surgery Using vNOTES Approach in Comparison to Conventional Laparoscopy: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Women aged from 18 to 70 years\n* Discernment capacity with oral and written consent signed\n* Heterosexual intercourse (with vaginal penetration) within four weeks prior to inclusion in the study\n\nExclusion Criteria:\n\n* History of rectal surgery.\n* Suspected rectovaginal\u002Fretrocervical endometriosis.\n* History of brachytherapy or pelvic radiation.\n* Suspected malignancy.\n* History of severe pelvic inflammatory disease.\n* Active lower genital tract infection.\n* Pregnancy.\n* Women who do not speak fluent French or English.\n* Patients under tutelage (with or without capacity of judgement).","70 Years",{"count":150,"type":21},62,[24],"Transvaginal Natural Orifice Transluminal Endoscopic Surgery (vNOTES) is a recent innovation in minimally invasive surgery which has already proven its non-inferiority to conventional abdominal laparoscopy (CAL) for hysterectomy in terms of efficiency and safety. However, the investigators note a lack of medical literature and no specific randomized controlled trial (RCT) assessing women's sexual function after vNOTES for benign adnexal surgery.\n\nThe aim of this RCT is to confirm the non-inferiority of the vNOTES approach for benign adnexal pathology compared to CAL on women's sexual function. Secondary outcomes will evaluate vNOTES's efficiency, morbidity and postoperative complications compared to CAL for benign adnexal surgery. The relationship between adnexal mass morcellation\u002Faspiration and the quality of the histological analysis on surgical specimens will also be evaluated as secondary outcome.",[154,155,156,157,158,159,160,28,161,162,163],"Gynecologic Disease","Adnexal Mass","Adnexal Cyst","Sexuality","Adnexal Diseases","Sexual Dysfunction","Quality of Life","Dyspareunia","Pelvic Pain","Complication","2025-03-24",{"date":166,"type":33},"2025-03-27",{"date":168,"type":33},"2024-01-01",{"date":170,"type":21},"2027-04-03",{"name":172,"class":40},"Jean Dubuisson",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":4,"eligibilityCriteria":179,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":180,"targetDuration":182,"studyType":53,"phases":4,"briefSummary":183,"conditions":184,"keywords":187,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":41},"100571028","optimising-renal-tumour-management-through-artificial-intelligence-modules-100571028","NCT06714916","Optimising Renal Tumour Management Through Artificial Intelligence Modules","Mutimodal Artificial Intelligence for Optimising Renal Tumour Management: Diagnosis, Surgery and Prognosis","Inclusion Criteria:\n\n* Patients with renal tumor which can be treated by surgery;\n* Complete CECT within 30 days before surgery;\n* Patients who fully understand this study and sign the informed consent;\n\nExclusion Criteria:\n\n* Patients with any item missing from the baseline clinical and pathological information;\n* Patients who has already metastasized by the time the tumor is discovered;\n* Previous treatment in any form, including surgery, targeted therapy and immunotherapy;",{"count":181,"type":21},2100,"5 Years","The goal of this observational study is to improve the management of people with renal tumour by multimodal artificial intelligence(AI). It will also measure the accuracy of the predictions from AI models. The main questions it aims to answer are:\n\n1. whether the AI module can accurately provide tumor-related information such as Benign or malignant, subtypes, grading, stage, etc. by learning from preoperative CT images.\n2. whether the AI module can help clinicians find out the most suitable surgical programme for people with renal tumor.\n3. whether the AI module can integrate CT images and pathology slides, offering supplementary prognostic information to improve postoperative survival.\n\nParticipants who complete a CT(usually Contrast-enhanced CT, CECT) examination and undergo radical or partial nephrectomy will carry out active surveillance and record postoperative survival data for 5 years.",[185,28,186],"Renal Neoplasms","Renal Cell Cancer",[188,189,190,191,192,193],"Articicial Intelligence","Renal tumors","Prediction Model","Surgery","Radiomics","Pathomics","2025-03-16",{"date":196,"type":33},"2025-03-19",{"date":198,"type":33},"2025-01-01",{"date":200,"type":21},"2033-12-31",{"name":202,"class":40},"Shao Pengfei",{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":4,"eligibilityCriteria":208,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":41},"100519676","blood-specimen-collection-for-laboratory-assay-research-100519676","NCT06046651","Blood Specimen Collection For Laboratory Assay Research","Inclusion Criteria:\n\n* Any gender, in good general health\n* Must be 18 years old or older, inclusive at enrollment\n* Must be willing to provide capillary blood samples via a fingerstick and venous blood samples, including self-collection and collection by a licensed healthcare professional\n* Must be able to read, understand, and willingly sign an Informed Consent Form (ICF) and complete a brief health questionnaire\n* Must be able to read, speak and understand English\n* Must be available to attend one study visit at Investigator's laboratory or a third-party laboratory designated by the Investigator or collect samples at home, at the discretion of the Investigator.\n\nExclusion Criteria:\n\n* Individuals who are unable to provide a blood sample due to any illness\n* Individuals participating in another research study, that the Investigator feels may compromise study outcomes\n* Individuals having an acute or chronic disease or medical condition, including pregnancy, which could excessively increase study risk in the opinion of the Investigator or compromise study outcomes\n* Individuals who are unlikely to be available for the duration of the study",{"count":210,"type":21},10000,"To collect lab data from capillary and venous blood specimens for use in analytical research studies to support the development and validation of laboratory procedures.",[213,159,214,28],"General; Metabolic Disorder","Hair Loss","2024-11-13",{"date":217,"type":33},"2024-11-14",{"date":219,"type":33},"2023-08-16",{"date":221,"type":21},"2033-08-15",{"name":223,"class":224},"Roman Health Ventures Inc.","INDUSTRY",{"id":226,"slug":227,"hasResults":11,"nctId":228,"briefTitle":229,"officialTitle":230,"acronym":4,"eligibilityCriteria":231,"healthyVolunteers":16,"sex":232,"minAge":233,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":243,"overallStatus":246,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":250,"completionDateStruct":252,"leadSponsor":254,"locationsCount":41},"100567017","artificial-intelligence-models-for-precision-prediction-and-treatment-of-prostate-cancer-100567017","NCT06662708","Artificial Intelligence Models for Precision Prediction and Treatment of Prostate Cancer","Accurate Prediction and Treatment of Prostate Cancer by Artificial Intelligence Model-based Whole Slide Images and MRIs","Inclusion Criteria:\n\n* Patients with suspected PCa (elevated PSA or suspicious positive lesions on ultrasound or MRI results);\n\nExclusion Criteria:\n\n* Previous treatment of the prostate in any form, including surgery, radiotherapy\u002Fchemotherapy, endocrine therapy, targeted therapy and immunotherapy;\n* Patients with any item missing from the baseline clinical and pathological information;\n* Patients with a history of other malignancies, serious comorbidities or other health problems;\n* Unable to provide\u002Fsign an informed consent form;\n* Patients who, in the judgement of the investigator, are deemed unfit to participate in this clinical trial;","MALE","30 Years",{"count":235,"type":21},200,[24],"The aim of this clinical trial is whether artificial intelligence models can be used for accurate clinical preoperative diagnosis and postoperative diagnosis of pathological findings, and will also measure the accuracy of the predictions made by the artificial intelligence models.The main target questions addressed by the model building are:\n\n1. whether the AI model can learn from preoperative MRI and postoperative Whole Slide Images so as to accurately predict information such as benignness or malignancy, aggressiveness, grading, subtypes, genes, etc. for participants suspected of having prostate cancer preoperatively\u002Fpuncturally.\n2. whether the AI model is capable of learning postoperative macropathology slides to enable outcome diagnosis of surgical pathology slides in new participants.\n\nParticipants will:\n\n1. complete an MRI examination and have their MRI images analysed by the established AI model to make an accurate diagnosis of them.\n2. Based on the diagnosis, if prostate cancer is predicted, they will undergo radical prostate cancer surgery and refine their surgical pathology.",[239,240,241,242,28],"Prostate Cancer","Prostate Intraductal Carcinoma","Prostate Cancer Aggressiveness","Prostate Cancer Stage",[188,244,245,239,190],"Whole Slide Image","mp-MRI","NOT_YET_RECRUITING","2024-10-27",{"date":249,"type":33},"2024-10-29",{"date":251,"type":21},"2024-12-01",{"date":253,"type":21},"2030-12-31",{"name":202,"class":40},{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":4,"eligibilityCriteria":261,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":262,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":271,"lastUpdatePostDateStruct":272,"startDateStruct":274,"completionDateStruct":276,"leadSponsor":278,"locationsCount":281},"100518800","ai-prediction-of-gastric-cancer-response-to-neoadjuvant-chemotherapy-100518800","NCT06035250","AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy","Deep Learning-Based Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy","Inclusion Criteria:\n\n* Age 18 years or older;\n* Pathologically diagnosed with advanced gastric cancer in accordance with the American AJCC's TNM staging standards;\n* Have not undergone any systematic anti-cancer treatments before neoadjuvant chemotherapy and have not had surgery for local progression or distant metastasis;\n* Received standard neoadjuvant chemotherapy as recommended by the clinical guidelines, and have documented treatment details;\n* CT imaging and biopsy pathology images strictly taken within one month prior to starting neoadjuvant treatment;\n* Patients possess comprehensive preoperative clinical information and post-operative TRG grading.\n\nExclusion Criteria:\n\n* Patients whose CT or pathology images are unclear, making lesion assessment infeasible;\n* Patients diagnosed with other concurrent tumors.",{"count":235,"type":21},"This study seeks to develop a deep-learning-based intelligent predictive model for the efficacy of neoadjuvant chemotherapy in gastric cancer patients. By utilizing the patients' CT imaging data, biopsy pathology images, and clinical information, the intelligent model will predict the post-neoadjuvant chemotherapy efficacy and prognosis, offering assistance in personalized treatment decisions for gastric cancer patients.",[265,266,28],"Gastric Cancer","Image",[265,268,192,269,193,270],"Neoadjuvant Chemotherapy","Treatment Outcome Prediction","Radiopathomics","2023-09-26",{"date":273,"type":33},"2023-09-28",{"date":275,"type":33},"2023-09-10",{"date":277,"type":21},"2029-12-31",{"name":279,"class":280},"Chinese Academy of Sciences","OTHER_GOV",22,{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":288,"eligibilityCriteria":289,"healthyVolunteers":11,"sex":17,"minAge":290,"maxAge":291,"enrollmentInfo":292,"targetDuration":4,"studyType":53,"phases":4,"briefSummary":294,"conditions":295,"keywords":302,"overallStatus":246,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":315},"100423060","development-of-a-predictive-model-for-the-risk-of-metastatic-disease-in-ppgls-a-retrospective-cohort-study-100423060","NCT04788927","Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study","Development of a Comprehensive Predictive Model for Risk of Metastatic Disease in PPGLs Based on a Combination of Clinical, Biochemical, Genetic, and Pathoanatomical Characteristics a Retrospective National Cohort Study","PPGL-Pred","Inclusion Criteria:\n\n* All Danish patients diagnosed with PPGLs or genetic variants that predispose to PPGLs since 1996 will be included.\n\nExclusion Criteria:\n\n* None from the initial data collection. If there are no tumour tissue or blood samples from a patient in the biobanks they will subsequently be excluded.","0 Years","120 Years",{"count":293,"type":21},400,"Phaeochromocytomas and paragangliomas (PPGLs) are tumours of the adrenal medulla and extra-adrenal sympathetic nervous system, some which can become metastatic. It is a very rare disease and the tumours are often detected late. Approximately 50 % of the tumours are caused by germline genetic variants screening programmes are recommended for patients and their family members; however, they are not yet well-targeted with respect to individual prognosis. In this study the investigatorscaim to characterize the genotype-phenotype associations in all Danish patients (n=400) diagnosed with PPGLs who have been followed in tertiary centres using medical records and national registries. To this end novel immunohistochemical, genetic, and epigenetic biomarkers in tumour tissues samples from biobank material (blood samples and tumour tissue) will be investigated to develop a comprehensive predictive algorithm for disease prognosis. The study will provide a clinical tool for an improved targeted screening program and subsequently prevention of disease development.",[296,297,298,28,299,300,301],"Paraganglioma","Pheochromocytoma","Genetic Predisposition to Disease","Somatic Mutation","Head and Neck Cancer","Neuroendocrine Tumors",[296,303,304,28,305],"Phaeochromocytoma","Clinical genetics","Translational research","2023-04-06",{"date":308,"type":33},"2023-04-07",{"date":310,"type":21},"2023-10-01",{"date":312,"type":21},"2027-09-30",{"name":314,"class":40},"Rigshospitalet, Denmark",2,{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":321,"acronym":4,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":323,"enrollmentInfo":324,"targetDuration":182,"studyType":53,"phases":4,"briefSummary":325,"conditions":326,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":41},"100399636","application-of-radiomics-in-breast-cancer-100399636","NCT04483804","Application of Radiomics in Breast Cancer","Application of Radiomics in Correlation Between Ultrasound Characteristics and Pathological Prognostic Factors in Breast Cancer","Inclusion Criteria:\n\nClinical diagnosis of breast cancer\n\nExclusion Criteria:\n\nMissing pathology Missing follow-up results Missing data","80 Years",{"count":52,"type":21},"Little is known about the correlation between ultrasound characteristics (conventional, elastography and contrast enhanced ultrasound (CEUS) )and pathological prognostic factors in breast cancer. The aim of this study was to explore the correlation between ultrasound characteristics and pathological prognostic factors using radiomics.",[57,327,328,28,192],"Ultrasound","Elastography","2023-03-09",{"date":331,"type":33},"2023-03-10",{"date":333,"type":33},"2018-01-01",{"date":335,"type":21},"2028-12",{"name":66,"class":40},{"id":338,"slug":339,"hasResults":11,"nctId":340,"briefTitle":341,"officialTitle":342,"acronym":4,"eligibilityCriteria":343,"healthyVolunteers":11,"sex":50,"minAge":18,"maxAge":4,"enrollmentInfo":344,"targetDuration":4,"studyType":22,"phases":346,"briefSummary":347,"conditions":348,"keywords":4,"overallStatus":246,"whyStopped":4,"lastUpdateSubmitDate":351,"lastUpdatePostDateStruct":352,"startDateStruct":354,"completionDateStruct":356,"leadSponsor":358,"locationsCount":41},"100435928","adjuvant-radiotherapy-in-patients-with-early-endometrial-cancer-100435928","NCT04956601","Adjuvant Radiotherapy in Patients With Early Endometrial Cancer","A Multicenter, Randomized, Controlled Trial of Adjuvant Radiotherapy in Patients With Early Endometrial Cancer Based on Moderate Risk Molecules Classification","Inclusion Criteria:\n\n1. Endometrial adenocarcinoma is confirmed by pathology, and the molecular types were microsatellite instability type and low copy type;\n2. Stage IA and grade 3 or stage IB (FIGO 2009), without substantial lymph-vascular space invasion;\n3. Surgery must have included a hysterectomy and bilateral adnexectomy. Pelvic lymph node sampling and para-aortic lymph node sampling are optional;\n4. ECOG score is 0-2;\n5. The interval time between surgery and radiotherapy is no more than 8 weeks;\n6. The routine blood examination was normal;\n7. Compliance is good and informed consent is voluntarily signed.\n\nExclusion Criteria:\n\n1. The patients receive chemotherapy;\n2. History of previous malignant disease;\n3. Previous diagnosis of Crohn's disease or ulcerative colitis.",{"count":345,"type":21},480,[24],"To compare the effect of vaginal brachytherapy as adjuvant treatment after operation when compared to pelvic external beam radiotherapy in patients with early endometrial cancer based on moderate risk molecules classification.",[349,28,350],"Endometrial Cancer","Radiotherapy","2021-07-02",{"date":353,"type":33},"2021-07-09",{"date":355,"type":21},"2021-07",{"date":357,"type":21},"2029-08",{"name":359,"class":40},"Peking University Third Hospital"]